Elasomeran + davesomeran (Spikevax bivalent original/Omicron BA.4-5)
- Status:
- Unclassified
- Decision Date:
- April 2023
Comments
Use as a booster dose for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals aged ≥12 years who have previously received at least a primary vaccination course against COVID-19.
search again